How to implement pre-emptive pharmacogenetic testing in the acute hospital setting
Your hospital has decided to introduce a pharmacogenomics program. What do you need to do to realize this ambition? In this paper, we set out the elements that should be considered, including the team and resources required to establish a sustainable program. This will draw on experience from successful global pharmacogenomic programs and will highlight key interdependencies, opportunities and challenges.
Authors
- Jessica Keen (ORCID: https://orcid.org/0009-0009-7708-8534)
- John McDermott (ORCID: https://orcid.org/0000-0002-5220-8837)
- Videha Sharma (ORCID: https://orcid.org/0000-0001-7640-1239)
- Charlotte Skitterall
- William G. Newman (ORCID: https://orcid.org/0000-0002-6382-4678)
- Ahmed Shoaib (ORCID: https://orcid.org/0000-0001-7480-1079)
Institutions
- University of Manchester (GB)
- Manchester University NHS Foundation Trust (GB)
Publication Details
- Journal
- Pharmacogenomics
- Published
- 2025-08-13
- DOI
- https://doi.org/10.1080/14622416.2025.2560295
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.00